Press release
Insmed To Present at the Nasdaq 47th Investor Conference
BRIDGEWATER, N.J., Nov. 30, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of
About this update from Insmed Incorporated
[{"type":"text","content":"BRIDGEWATER, N.J., Nov. 30, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 47th Investor Conference in London on Wednesday, December 7 at 8:30 a.m. EST/1:30 p.m. GMT.\nThe fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.\nAbout Insmed\nInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.\nContact:\nInvestors:\nEleanor BarisserAssociate Director, Investor Relations Insmed(718) [email protected] \nMedia:\nMandy Fahey Executive Director, Corporate CommunicationsInsmed(732) [email protected]\n\n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-nasdaq-47th-investor-conference-301689674.html\nSOURCE Insmed Incorporated","length":4036,"tagName":"div"}]